Metastatic sarcoma is a sarcoma that has spread from its original location to distant parts of the body. Sarcomas are cancers that arise in connective tissues like muscle, fat, bone, cartilage, and blood vessels, and when they metastasize, the lungs are by far the most common destination. The five-year relative survival rate for distant-stage soft tissue sarcoma is about 17%, though outcomes vary significantly depending on the specific subtype, where the cancer has spread, and how it responds to treatment.
How Sarcoma Spreads
Sarcoma cells spread through a multi-step process. First, cells at the original tumor site develop the ability to break away and invade surrounding tissue. They then enter the bloodstream or lymphatic system, travel through circulation, exit into a new organ, and establish a new tumor there. During this journey, tumor cells in the blood form clusters with platelets and immune cells, which help them stick to blood vessel walls and survive the trip.
What makes this possible at a cellular level is a shift in how the cancer cells behave. They take on properties that let them move more freely, resist stress, and anchor themselves in unfamiliar tissue. Not every cell that enters the bloodstream succeeds. Most die. But the ones that complete the full journey and colonize a new site are what create metastatic disease.
Where Metastatic Sarcoma Typically Appears
The lungs dominate. In a retrospective study of patients who died from distant metastases, 83% developed lung metastasis as the first site of spread. This held especially true for bone sarcomas, where every patient in the study who died of metastatic disease had lung involvement.
Extra-pulmonary spread occurred in about 35% of cases, most often to bone, followed by the liver, soft tissue, and brain. Some patients developed metastases in unusual locations like the heart, pelvic cavity, or stomach. Around 16% of soft tissue sarcoma patients who died had only extra-pulmonary metastases with no lung involvement at all, which means lung-only screening can occasionally miss spread to other organs.
Symptoms of Metastatic Sarcoma
Symptoms depend almost entirely on where the cancer has landed. Lung metastases often cause shortness of breath and fatigue, though small lesions can be completely silent and found only on imaging. Bone metastases typically produce localized pain that worsens over time, sometimes leading to fractures in weakened bone. Brain metastases may cause headaches, weakness on one side of the body, or difficulty speaking.
Cardiac metastases are rare but illustrate how unpredictable symptoms can be. When sarcoma spreads to the heart, it can trigger heart rhythm problems, heart failure, chest pain, or fluid buildup around the heart. In some cases, tumor fragments can break off and block blood vessels elsewhere, causing stroke-like symptoms such as sudden numbness, one-sided weakness, or loss of speech. Many cardiac metastases produce no symptoms at all in their early stages and are only caught through imaging done for other reasons.
How It’s Diagnosed
CT scans of the chest are the standard tool for detecting lung metastases, since the lungs are the primary site of spread. For a more complete picture, PET/CT scans can detect metabolically active tumor deposits throughout the body, making them useful for staging and for finding an unknown primary tumor when metastatic disease is discovered first. PET/CT also helps identify which tumor site is most likely to give useful information if a biopsy is needed.
Biopsy of a metastatic lesion confirms the diagnosis and can reveal whether the tumor’s characteristics have changed from the original sarcoma, which sometimes influences treatment decisions. MRI is often used for specific areas like the brain or spine when metastasis to those locations is suspected.
Staging
Under the current AJCC staging system (8th edition), soft tissue sarcoma of the trunk and extremities is classified as stage IV when it has spread to regional lymph nodes or to distant sites. Any sarcoma with confirmed distant metastasis is stage IV regardless of the size or grade of the original tumor. This distinction matters because stage IV disease is treated as a systemic illness rather than a localized one, shifting the focus from surgery alone to body-wide therapies.
Chemotherapy for Metastatic Sarcoma
Chemotherapy remains the backbone of treatment for advanced soft tissue sarcoma. The primary drug has been the same since 1973: doxorubicin, an anthracycline that is still the standard first-line option. Used alone, it shrinks tumors in roughly 14% to 20% of patients and holds the cancer stable for a median of about 4.6 to 6.8 months.
Adding ifosfamide to doxorubicin improves response rates to 21% to 38%, with a median progression-free survival of 5.6 to 11 months. A three-drug combination that also includes dacarbazine achieves the highest reported response rate at 38% with a median progression-free survival of 9.8 months, though more drugs also means more side effects. The choice between single-agent and combination therapy often comes down to how well a patient can tolerate treatment and how urgently the tumor needs to shrink.
These numbers highlight a hard reality: chemotherapy controls metastatic sarcoma temporarily for most patients rather than eliminating it. Response rates are modest compared to many other cancers, which is why research into newer approaches has intensified.
Targeted Therapy and Immunotherapy
Pazopanib, a drug that blocks the growth of blood vessels feeding the tumor, is approved for advanced soft tissue sarcoma after chemotherapy has stopped working. It offers another line of defense, though it is not curative.
Immunotherapy has a more limited role in sarcoma than in cancers like melanoma or lung cancer, but there are exceptions. Atezolizumab, a PD-L1 inhibitor, is the only immunotherapy currently FDA-approved specifically for sarcoma, and its approval is limited to alveolar soft part sarcoma, a rare subtype. For the same subtype, a combination of axitinib (a blood vessel growth inhibitor) and pembrolizumab (a PD-1 inhibitor) is now a preferred first-line option in national treatment guidelines, though this combination lacks formal FDA approval.
Clinical trials combining targeted drugs with immunotherapy have shown promising results in certain subtypes. A phase 2 study in angiosarcoma combining cabozantinib and nivolumab produced a 62% response rate. Another trial pairing pazopanib with durvalumab in a broader group of soft tissue sarcomas saw a 30% response rate. These are still early-stage results, and responses vary dramatically by sarcoma subtype, reinforcing the importance of identifying the exact type of sarcoma when making treatment decisions.
Surgery and Radiation for Symptom Relief
When metastatic sarcoma causes pain, bleeding, or pressure on vital structures, radiation therapy can provide relief relatively quickly. A typical palliative course involves a short, intensive schedule delivered over about two and a half weeks. The goal is not to cure the disease but to shrink problematic deposits enough to reduce symptoms and maintain quality of life.
Surgery also plays a role in select situations. Some patients with a limited number of lung metastases undergo surgical removal of those nodules, which can extend survival in carefully chosen cases. For locally advanced tumors that have failed other treatments and are causing severe symptoms, amputation or wide excision may be considered as a last resort for comfort. In some cases, surgically removing metastatic deposits is followed by radiation to the surgical site to reduce the chance of local regrowth.
Prognosis and What Affects It
The 17% five-year survival rate for distant-stage soft tissue sarcoma, based on patients diagnosed between 2015 and 2021, reflects the overall picture but masks significant variation. Patients with a single, resectable lung metastasis do considerably better than those with widespread disease in multiple organs. Tumor grade, subtype, and response to initial chemotherapy all influence how the disease progresses.
Sarcoma is not one disease. There are more than 70 recognized subtypes, and they behave differently. Some, like alveolar soft part sarcoma, grow slowly even after spreading, while others are highly aggressive. This is why treatment for metastatic sarcoma increasingly depends on identifying the specific subtype and matching it with the most effective available therapy rather than applying a one-size-fits-all approach.